For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

< Back to Agenda
Current Use of iPSC to Fill Unmet Clinical Gaps
Wednesday, September 4, 2024 09:15 AM - 10:15 AM  
F2
Concurrent Session
Chair:
  •  Anna Falk, PhD, Lund University/CCRM Nordic, Sweden 
Speakers: 
  • Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, United Kingdom - Scaling Success: Overcoming Hurdles in Clinical-Grade iPSC Production and Application
  • Begoña Aran, PhD, Bellvitge Biomedical Research Institute (IDIBELL), Spain - Allogeneic hiPSC from homozygous UCB units for high prevalence haplotypes (IPS-PANIA)
  • Massimiliano Gnecchi, MD, PhD, University of Pavia, Italy - Use of iPSC for cardiovascular disease modeling and drug screening
In recent years, the production process of induced pluripotent cells (iPSCs) and terminally differentiated cells derived from iPSCs has drastically improved. This has made it possible to develop reliable protocols utilizing iPSC-based technologies not only for therapeutic application but also for disease modeling and drug testing. The speakers will provide examples of how we can currently use this technology, giving us an idea of how close we really are to their application in a clinical setting.

Session Objectives
  1. Learning about the challenges and possible solutions to produce iPSC applicable for clinical use
  2. Learning about the most recent applications of iPSC technology 
  3. Understanding how the iPSC technology can be used to model certain diseases
  4. Understanding how the iPSC technology can be used to test new drugs
Anna Falk PhD
Professor
 Lund University
 Chair
Begoña Aran
Barcelona Stem Cell Bank Coordinator
 IDIBELL
 Speakers
Jacqueline Barry PhD
Chief Clinical Officer
 Cell and Gene Therapy Catapult
 Speakers
Massimiliano Gnecchi
Professor of Cardiology
 University of Pavia & IRCCS Policlinico San Matteo
 Speakers
< Back to Agenda